NCT07216703 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07216703
Title	A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Recruitment	Recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	cervical squamous cell carcinoma cervical adenocarcinoma cervical adenosquamous carcinoma
Therapies	Pembrolizumab + SKB264 Cisplatin + Paclitaxel + Pembrolizumab Bevacizumab + Pembrolizumab + SKB264 Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
TRIALS 365 ( Site 6008)	RECRUITING	Shreveport	Louisiana	71103	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07216703Clinical Trial Detail